生物股份(600201.SH)半年度淨利潤降52.67%至1.7億元
格隆匯8月22日丨生物股份(600201.SH)發佈2019年半年度報告，實現營業收入5.11億元，同比下降32.85%；歸屬於上市公司股東的淨利潤1.70億元，同比下降52.67%；歸屬於上市公司股東的扣除非經常性損益的淨利潤1.66億元，同比下降52.05%；基本每股收益0.15元。
2019年上半年，受非洲豬瘟疫情常態化影響，國內生豬出欄量出現大幅下降，生豬養殖行業遇到前所未有的挑戰。面對嚴峻的行業形勢和突發的市場變化，公司管理層在新一屆董事會的帶領下，堅持總體戰略指導不放鬆，以品質為原則、市場為導向，創新為驅動，提升產品質量，調整產品銷售結構，採取有針對性的銷售策略，以智能製造和智慧防疫為護城河，再次提升公司核心競爭力，積極應對非洲豬瘟疫情對動保行業及公司經營帶來的不利影響。
上半年，金宇生物科技產業園區一期項目進展順利，口蹄疫疫苗車間完成機電安裝和內部施工，滅活疫苗、弱毒活疫苗、布魯氏桿菌疫苗三個車間通過GMP靜態驗收，所有車間預計將在下半年完成GMP動態驗收，年底前可全部投產運營。新園區智能製造將疫苗生產工藝參數、質量標準、操作規程和數字化生產線與西門子工業4.0控制技術深度融合，實現了疫苗製造全生命週期在最優選工藝參數下完成，進一步提升公司核心競爭力。
公司充分發揮三個國家級實驗室和四地研發分工佈局優勢，將新品研發與市場需求緊密結合，提升自主研發能力，在寵物多聯多價疫苗、藥品與診斷試劑研製方面進行技術革新。報告期內，公司獲得專利授權3項，申請發明專利2項，取得呼吸綜合徵嵌合病毒活疫苗(PC株)生產文號，塞內卡病毒滅活疫苗，豬傳染性腸胃炎、豬流行性腹瀉二聯活疫苗，犬三聯活疫苗等研發項目進展順利。
報告期內，非洲豬瘟疫情導致生豬養殖規模持續下降，公司疫苗銷售壓力陡增。公司營銷體系通過市場分析，結合規模化養殖主體具體情況和實際需求，積極採取有針對性的銷售策略，全面推行一省一策和一場一策的銷售策略，保持口蹄疫等豬用疫苗的市場份額穩定。同時，根據市場變化，對產銷結構進行調整，在禽用疫苗和反芻疫苗等領域方面加大銷售力度，取得了良好的營銷效果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
